Literature DB >> 16919734

Naltrexone for probationers and parolees.

Charles O'Brien1, James W Cornish.   

Abstract

Heroin addiction is a chronic disorder that is usually associated with crimes aimed to obtain funds for the purchase of this illegal drug. When these addicted individuals are apprehended and incarcerated, they temporarily obtain drug-free status, but relapse quickly upon release. There is a medication approved by the Food and Drug Administration (naltrexone) that could prevent relapse and thus break this revolving door cycle. In combination with counseling, former inmates could devote energies to legal jobs or job training instead of drug seeking. The major reasons for the nonuse of this medication appear to be lack of knowledge about the medication and fear that the use of a medication that blocks opiate receptors is somehow unethical. This special issue presents data, discussions, and suggestions regarding the ethical use of naltrexone in incarcerated populations or in those under supervision for parole or probation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919734     DOI: 10.1016/j.jsat.2006.06.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  15 in total

Review 1.  Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.

Authors:  Evgeny Krupitsky; Edwin Zvartau; George Woody
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint?

Authors:  Joseph Frascella; Marc N Potenza; Lucy L Brown; Anna Rose Childress
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Antagonist Models for Relapse Prevention and Reducing HIV Risk.

Authors:  George E Woody; Evgeny Krupitsky; Edwin Zvartau
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-27       Impact factor: 4.147

5.  A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Tamara Y Boney; Cynthia A Clark; Joshua D Lee; Peter D Friedmann; Edward V Nunes; Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Elie S Nuwayser; Charles P O'Brien
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

6.  Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts.

Authors:  Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; Shannon Gwin Mitchell; Barry S Brown
Journal:  Drug Alcohol Depend       Date:  2010-12-03       Impact factor: 4.492

7.  Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

Authors:  Elisha M Wachman; Kelley Saia; Melissa Miller; Eduardo Valle; Hira Shrestha; Ginny Carter; Martha Werler; Hendree Jones
Journal:  Clin Ther       Date:  2019-07-27       Impact factor: 3.393

8.  Medication-assisted treatment research with criminal justice populations: challenges of implementation.

Authors:  Michael S Gordon; Timothy W Kinlock; Patrice M Miller
Journal:  Behav Sci Law       Date:  2011 Nov-Dec

9.  Medication-Assisted Treatment and Violent Outcomes in Community-Based Offenders with Alcohol and Drug Use Problems.

Authors:  Sarah L Desmarais; Julie S Gray; Candalyn B Rade; Amy M Cohn; Stephen Doherty; Kevin Knight
Journal:  Psychol Violence       Date:  2016-03-24

10.  Drug abuse treatment beyond prison walls.

Authors:  Carl Leukefeld; Carrie B Oser; Jennifer Havens; Michele Staton Tindall; Jennifer Mooney; Jamieson B Duvall; Hannah Knudsen
Journal:  Addict Sci Clin Pract       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.